Fig 1: Transwell experimental results. (a) The migration and invasion ability of HCT116 decreased after overexpression of GPD1L, (b) The migration and invasion ability of SW620 decreased after overexpression of GPD1L (**P<0.01, ***P<0.001).
Fig 2: Relationship between GPD1L expression level and clinicopathological features. (a) TCGA database, (b) Data from the center.
Fig 3: The expression differences of GPD1L in clinical specimens and CRC cells. (a) Differences in the expression of GPD1L in 58 CRC patients and donor-matched normal tissues (***P<0.001), (b) Differences in the expression of GPD1L in normal colonic epithelial cell lines (NCM460) and five CRC cell lines (SW620, HCT1161, SCT116, DLD 480 and LOVO) (ns P>0.05, *P<0.05, **P<0.01, ***P<0.001).
Fig 4: Enrichment plots from the gene set enrichment analysis (GSEA). GSEA results showing differential enrichment of genes in KEGG with GPD1L expression.
Fig 5: Transfected with GPD1L overexpression plasmid. (a) Transfection efficiency at the mRNA level of GPD1L overexpression plasmid, (b) Transfection efficiency at the protein level of GPD1L overexpression plasmid in HCT116 cells, (c) Transfection efficiency at the protein level of GPD1L overexpression plasmid in SW620 cells (**P<0.01, ***P<0.001, ****P<0.0001).
Supplier Page from Abcam for Recombinant Human GPD1L protein (His tag N-Terminus)